Literature DB >> 30587519

Simultaneous CMV and Listeria infection following alemtuzumab treatment for multiple sclerosis.

Agustín Pappolla1, Luciana Midaglia2, Claudia P Boix Rodríguez1, Adaia Albasanz Puig1, Maiylyi Lung1, Isabel Ruiz Camps1, Joaquín Castilló1, Patricia Mulero1, Angela Vidal-Jordana1, Georgina Arrambide1, Breogán Rodriguez-Acevedo1, Jaume Sastre-Garriga1, Jordi Río1, Manuel Comabella1, Ingrid Galán1, Mar Tintoré1, Xavier Montalbán1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30587519      PMCID： PMC6382059          DOI： 10.1212/WNL.0000000000006801

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  7 in total

1.  Hepatic microabscesses during CMV reactivation in a multiple sclerosis patient after alemtuzumab treatment.

Authors:  Stefania Barone; Sara Scannapieco; Carlo Torti; Enrica Filippelli; Vincenzo Pisani; Alfredo Granata; Domenico Console; Giulio Demonte; Tiziana Tallarico; Serena Polidoro; Aldo Quattrone; Paola Valentino
Journal:  Mult Scler Relat Disord       Date:  2017-12-18       Impact factor: 4.339

2.  Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab.

Authors:  Marinella Clerico; Stefania De Mercanti; Carlo Alberto Artusi; Luca Durelli; Robert T Naismith
Journal:  Mult Scler       Date:  2017-02-01       Impact factor: 6.312

3.  Summary of the International Consensus Symposium on Advances in the Diagnosis, Treatment and Prophylaxis and Cytomegalovirus Infection.

Authors:  J T van der Meer; W L Drew; R A Bowden; G J Galasso; P D Griffiths; D A Jabs; C Katlama; S A Spector; R J Whitley
Journal:  Antiviral Res       Date:  1996-11       Impact factor: 5.970

4.  Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis--Report of Two Cases.

Authors:  Daniela Rau; Michael Lang; Andreas Harth; Markus Naumann; Frank Weber; Hayrettin Tumani; Antonios Bayas
Journal:  Int J Mol Sci       Date:  2015-06-29       Impact factor: 5.923

Review 5.  Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis.

Authors:  Hans-Peter Hartung; Orhan Aktas; Alexey N Boyko
Journal:  Mult Scler       Date:  2014-10-24       Impact factor: 6.312

6.  Listeria monocytogenes infection associated with alemtuzumab - - a case for better preventive strategies.

Authors:  Trygve Holmøy; Hedda von der Lippe; Truls Michael Leegaard
Journal:  BMC Neurol       Date:  2017-04-04       Impact factor: 2.474

Review 7.  The global burden of listeriosis: a systematic review and meta-analysis.

Authors:  Charline Maertens de Noordhout; Brecht Devleesschauwer; Frederick J Angulo; Geert Verbeke; Juanita Haagsma; Martyn Kirk; Arie Havelaar; Niko Speybroeck
Journal:  Lancet Infect Dis       Date:  2014-09-15       Impact factor: 25.071
  7 in total
  4 in total

1.  Listeriosis in a Metropolitan Hospital: Is Targeted Therapy a Risk Factor for Infection?

Authors:  Fanfan Xing; Simon K F Lo; Susanna K P Lau; Patrick C Y Woo
Journal:  Front Med (Lausanne)       Date:  2022-04-29

Review 2.  The Meaning of Immune Reconstitution after Alemtuzumab Therapy in Multiple Sclerosis.

Authors:  Simona Rolla; Alessandro Maglione; Stefania Federica De Mercanti; Marinella Clerico
Journal:  Cells       Date:  2020-06-03       Impact factor: 6.600

3.  Incidence and Predictive Risk Factors of Infective Events in Patients With Multiple Sclerosis Treated With Agents Targeting CD20 and CD52 Surface Antigens.

Authors:  Emanuela Zappulo; Antonio Riccardo Buonomo; Francesco Saccà; Cinzia Valeria Russo; Riccardo Scotto; Giulia Scalia; Agostino Nozzolillo; Roberta Lanzillo; Grazia Tosone; Ivan Gentile
Journal:  Open Forum Infect Dis       Date:  2019-10-21       Impact factor: 3.835

Review 4.  Safety of Newer Disease Modifying Therapies in Multiple Sclerosis.

Authors:  Georges Jalkh; Rachelle Abi Nahed; Gabrielle Macaron; Mary Rensel
Journal:  Vaccines (Basel)       Date:  2020-12-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.